Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice

Publisher： Karger

E-ISSN： 1421-9913|76|5-6|216-226

ISSN： 0014-3022

Source： European Neurology, Vol.76, Iss.5-6, 2016-10, pp. : 216-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice

By  

European Neurology, Vol. 72, Iss. 1-2, 2014-06 ,pp. : 95-102

Karger

Access to resources Recommend Favorite

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

By  

European Neurology, Vol. 71, Iss. 5-6, 2014-02 ,pp. : 271-279

Karger

Access to resources Recommend Favorite

Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-11 ,pp. : 178-185

Karger

Access to resources Recommend Favorite

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity

By  

European Neurology, Vol. 75, Iss. 5-6, 2016-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

Advances in the Management of Multiple Sclerosis Spasticity: Multiple Sclerosis Spasticity Nervous Pathways

By  

European Neurology, Vol. 72, Iss. 1, 2014-09 ,pp. : 6-8

Karger

Access to resources Recommend Favorite